Escalating and de-escalating treatment in HER2-positive early breast cancer

详细信息    查看全文

• 作者：Heikki Joensuu ; ^{heikki.joensuu@hus.fi}
• 关键词：Breast cancer ; Human epidermal growth factor receptor 2 ; Trastuzumab
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：52
• 期：Complete
• 页码：1-11
• 全文大小：349 K
• 卷排序：52

文摘

Adjuvant regimens with < 12 months of trastuzumab have not been found inferior to the standard duration, but the follow-up times are still short. Dual inhibition of HER2 improves the pCR rates in the neoadjuvant setting and is a potential strategy to improve survival in the adjuvant setting. Two years of adjuvant trastuzumab confers no benefit over 1 year of trastuzumab. Extending therapy with oral HER2-inhibitors shows promise. Adjuvant treatments of short duration exploiting dual HER2 inhibition are being explored.